Results of a phase I dendritic cell vaccine trial for malignant astrocytoma: potential interaction with adjuvant chemotherapy

Walker, David G.; Laherty, Richard; Tomlinson, Francis H.; Chuah, Teong; Schmidt, Chris

doi:10.1016/j.jocn.2007.08.007

Cited by 72 publications

(52 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite the widespread use of radiation therapy and chemotherapy following resection, the median survival time is less than 12 months for patients with GBM. 1 Adjuvant treatments, including photodynamic therapy, 2 antiangiogenic therapy 3 and immunotherapy, 4 have been shown to increase the median survival time of GBM patients. However, GBM remains incurable.…”

Section: Introductionmentioning

confidence: 99%

Wnt inhibitory factor-1 regulates glioblastoma cell cycle and proliferation

Wu¹,

Jia-sheng²,

Yang

et al. 2012

Journal of Clinical Neuroscience

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Wnt inhibitory factor-1 regulates glioblastoma cell cycle and proliferation

Wu¹,

Jia-sheng²,

Yang

et al. 2012

Journal of Clinical Neuroscience

View full text Add to dashboard Cite

“…[1][2][3] DCs-based immunotherapy against cancer has displayed promising treatment outcome and becomes the centerpiece of clinical trials for active immunotherapy strategies. [4][5][6][7][8][9][10] In general, most study employed peripheral blood mononuclear cells (PBMCs) or peripheral blood stem cells (PBSCs) monocytes, which are first stimulated to immature DCs before cells are loaded with DNA, total RNA of defined tumor antigen by electroporation, which proves to be a more efficient and frequently used method for Ag loading of DCs when compared to other means. 11,12 Such DCs are very efficient in Ag uptake by cell endocytosis.…”

Section: Introductionmentioning

confidence: 99%

Addition of CpG ODN and Poly (I:C) to a standard maturation cocktail generates monocyte-derived dendritic cells and induces a potent Th1 polarization with migratory capacity

Zhu

Wang

et al. 2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Monocyte-derived dendritic cells (DCs) are used as immunoadjuvant cells in cancer vaccines and have made great progress. However, an optimal DCs subset is vital for this treatment effect, the current 'gold standard' cytokine cocktail DCs have a shortcoming in their cytokines secretion, especially IL-12p70, mainly because of the existence of PGE2. Therefore, it is necessary to find an appropriate DCs-based immunotherapeutic protocol. In this study, we compared a novel 'improved' maturation cytokine cocktail with the current 'gold standard' maturation cytokine cocktail used for generating standard DCs. The 'improved' maturation cytokine cocktail DCs showed a higher levels surface markers expression (CD80, CD83, CD86 and HLA-DR), the chemokine receptors CXCR4 and CCR7 and chemokine CCL19, CCL21 and CXCL21, whereas CCR5 expression was reduced. Most importantly, in contrast to 'gold standard' DCs, which secrete little IL-12p70 and as a result induce mainly Th2 immunity, 'improved' cytokine cocktail DCs secreted higher levels IL-12p70 and also secreted similar concentration IL-10. To removal of PGE2 from the 'improved' DCs did increase the IL-12p70 production. In conclusion, we here present the 'improved' DCs, as an optimal maturation cocktail protocol, can induce high migratory potential, generate immunostimulatory DCs, produce higher levels IL-12p70 with superior capacity to induce Th1 immunity, when compared with the 'gold standard' DCs.

show abstract

“…Since no glioma-specific, immunologicrelevant tumour-associated antigens (TAAs) have been identified, several approaches were considered to provide these antigens. One method uses whole-tumour homogenates made from surgically resected tumour (Rutkowski et al 2004;Yu et al 2004;Yamanaka et al 2005;Walker et al 2008;Wheeler et al 2008). Although this method is quite rapid to obtain TAAs, the contamination of these tumour homogenates by normal cells such as normal glial cells, fibroblasts, endothelial cells, microglial cells and macrophages, could induce autoimmunity after their injection.…”

Section: Introductionmentioning

confidence: 99%

Human glioma cell culture: two FCS-free media could be recommended for clinical use in immunotherapy

Clavreul

Jean

Preisser

et al. 2009

In Vitro Cell.Dev.Biol.-Animal

View full text Add to dashboard Cite

Immunotherapy, particularly active vaccination, may be developed as an effective and safe treatment modality for malignant gliomas, which continue to have a poor prognosis, despite advances in surgical techniques and adjuvant chemotherapy and radiotherapy. Since no glioma-specific tumor-associated antigens (TAAs) have been discovered, autologous tumor cells or well-established glioma cell lines could be used in future vaccination protocols to induce antitumour immunity against unknown TAAs. One obstacle for clinical use of these tumour cell vaccines is related to foetal calf serum (FCS). Efforts are currently being directed toward developing FCS-free media and serum-free alternatives to culture these cell vaccines. In this study, a medium containing human serum and one serum-free medium (UltraCulture), supplemented or not with epidermal growth factor, were tested on morphology, survival, DNA content and TAA expression of human glioma cell lines and glioma biopsy primary cultures. Their effects were compared on FCS-containing medium. Results show that, whatever the medium used, no significant variations in morphology and survival were observed. Furthermore, human serum-containing medium or UltraCulture preserved at early passage cultures the cell population of interest present in the biopsies before culture. In addition, the expression profile of eight TAAs was similar between these media. These data indicate that human serum-containing medium and UltraCulture serum-free medium could be promising candidates to produce tumour-cell vaccines.

show abstract

Results of a phase I dendritic cell vaccine trial for malignant astrocytoma: potential interaction with adjuvant chemotherapy

Cited by 72 publications

References 38 publications

Wnt inhibitory factor-1 regulates glioblastoma cell cycle and proliferation

Wnt inhibitory factor-1 regulates glioblastoma cell cycle and proliferation

Addition of CpG ODN and Poly (I:C) to a standard maturation cocktail generates monocyte-derived dendritic cells and induces a potent Th1 polarization with migratory capacity

Human glioma cell culture: two FCS-free media could be recommended for clinical use in immunotherapy

Contact Info

Product

Resources

About